A new mechanism for blocking myeloid-derived suppressor cells by CpG

Clin Cancer Res. 2011 Apr 1;17(7):1645-8. doi: 10.1158/1078-0432.CCR-11-0024. Epub 2011 Feb 2.

Abstract

In this issue of Clinical Cancer Research, Zoglmeier and colleagues show that CpG, via the induction of IFN-α, matures myeloid-derived suppressor cells to abrogate immune suppression in 2 murine solid tumor models.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • DNA / pharmacology*
  • DNA / therapeutic use
  • Humans
  • Immune Tolerance*
  • Immunotherapy
  • Myeloid Cells / drug effects
  • Myeloid Cells / immunology*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Oligodeoxyribonucleotides
  • Toll-Like Receptor 9 / agonists*

Substances

  • Antineoplastic Agents
  • CpG ODN 1826
  • Oligodeoxyribonucleotides
  • Toll-Like Receptor 9
  • DNA